Nykode Therapeutics enters multi-target license and collaboration agreement with Regeneron
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Owkin builds best-in-class predictive biomedical AI models and robust data sets
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
It is used for the treatment of advanced colorectal and gastric cancer
Taluka level transplant centre will add convenience to patients from rural areas
Nelarabine is in a class of medications called antimetabolites
Subscribe To Our Newsletter & Stay Updated